Loading clinical trials...

Assessment of the Social Cost of Crohn's Disease: Economic and Quality of Life Aspects (Study P04560) | Clinical Trials | Clareo Health

COMPLETED

Assessment of the Social Cost of Crohn's Disease: Economic and Quality of Life Aspects (Study P04560)

Assessment of the Social Cost of Crohn's Disease (COsto Sociale Della Malattia di CrOhn - COSMO): Economic and Quality of Life Aspects

NCT00723840•Merck Sharp & Dohme LLC

View on ClinicalTrials.gov

Summary

This observational study will evaluate the social cost and quality of life of participants who have had Crohn's Disease for at least 6 months and have active disease despite drug therapy. Participants are followed for a total of 18 months.

Detailed Description

Participants for this study will be enrolled from 25 gastroenterology sites, even spread across Italy. Each center will enroll between 10 and 40 participants each.

Eligibility

Age

18 - 70 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•participant must:
•* be between 18 and 70 years of age,
•* have active Crohn's disease (CD) with CDAI score \>= 150 (as per amended protocol) in spite of drug therapy, or active fistulizing disease,
•* be diagnosed with CD for at least 6 months,
•* sign the informed consent,
•* be capable of understanding the study and replying to the questionnaires.

Exclusion Criteria

•Participants who are unreliable in filling out questionnaires,
•Participants with diseases which may interfere with the cost's of CD or its complications,
•Participants who are participating in a clinical trial

Key Dates

Start Date

September 1, 2006

Primary Completion Date

December 1, 2009

Completion Date

December 1, 2009

Last Updated

July 30, 2015

Enrollment

245

ACTUAL participants

Conditions

Inflammatory Bowel DiseaseCrohn's Disease

Interventions

Observational Studies: participants treated according to the real clinical practice.

OTHER

A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

NCT06226883

Inflammatory Bowel DiseasesCrohn's Disease

View study

RECRUITINGNA

Impact of Morning Light Therapy in IBD

NCT07207200

Inflammatory Bowel Disease

View study

RECRUITINGPHASE3

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 30, 2015Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Assessment of the Social Cost of Crohn's Disease: Economic and Quality of Life Aspects (Study P04560)

Inclusion Criteria

Exclusion Criteria

A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

Impact of Morning Light Therapy in IBD

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

DB-3Q bmMSC-EVs in Patients With Perianal Fistulizing Crohn's Disease

Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)

ALPCO/Calprotectin CLIA Assay: Expected Values of Calprotectin in Healthy Subjects